Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “225 mg/m2 a day, 5 days/week for 5 weeks during radiotherapy period”In the company’s words, NCT02465593 on ClinicalTrials.gov
- Tested for
- Rectal Cancer
- Main trialPhase 1/2
- “This phase Ib/II study is a prospective, open-label, single arm, nonrandomized study of PEP503(radio-enhancer). There are 2 portions in this study. * Escalation phase (Part Ib): A 3 + 3 dose escalation study design will be adopted in this phase to identify the recommended injection volume of PEP503 for intratumor injection. * Expansion phase (Part II): Following the confirmation of the recommended volume of intratumor injection, 18 additional patients will be enrolled at the recommended volume level to evaluate for efficacy.”In the company’s words, NCT02465593 on ClinicalTrials.gov
- Other names
- 5-FU
Other drugs for Rectal Cancer
- 9-valent Human Papillomavirus Recombinant VaccineShanghai Bovax Biotechnology Co., Ltd. · Phase 3
- DostarlimabGSK · Phase 3
- CalderasibMerck & Co. · Phase 3
- IP-001Immunophotonics, Inc. · Phase 2/3
- AdagrasibMirati Therapeutics Inc. · Phase 3
- EncorafenibPfizer · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Terminated | 28 Jul 2021 | A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026